2020
Clinical Implications of Unique Drug Interaction Between Extended Release Tacrolimus and Phenytoin
Harkness TM, Cohen EA, Asch WS, Belfield KD. Clinical Implications of Unique Drug Interaction Between Extended Release Tacrolimus and Phenytoin. Progress In Transplantation 2020, 30: 177-178. PMID: 32233829, DOI: 10.1177/1526924820913500.Peer-Reviewed Original Research
2016
Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report
Merola J, Yoo PS, Schaub J, Smith JD, Rodriguez-Davalos MI, Tichy E, Mulligan DC, Asch W, Formica R, Kashgarian M, Kulkarni S. Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report. Transplantation Proceedings 2016, 48: 3106-3108. PMID: 27932157, DOI: 10.1016/j.transproceed.2016.04.005.Peer-Reviewed Original ResearchConceptsCalcineurin inhibitorsHemolytic uremic syndromeThrombotic microangiopathyKidney transplantationUremic syndromeMinimization of CNIsAtypical hemolytic uremic syndromeWithdrawal of tacrolimusEarly graft lossFavorable clinical courseGraft dysfunctionGraft lossImmunosuppression strategiesUsual therapyClinical courseCase reportCTLA-4Endothelial reactionFrequent causeChallenging causeUncontrolled activationMonoclonal antibodiesCellular destructionMicroangiopathyComponent C5
2015
Renal cancer in kidney transplanted patients
Frascà GM, Sandrini S, Cosmai L, Porta C, Asch W, Santoni M, Salviani C, D’Errico A, Malvi D, Balestra E, Gallieni M. Renal cancer in kidney transplanted patients. Journal Of Nephrology 2015, 28: 659-668. PMID: 26202137, DOI: 10.1007/s40620-015-0219-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCalcineurin inhibitorsRenal cancerNative kidneysKidney diseaseWithdrawal of CNIsChronic allograft nephropathyAutosomal dominant polycystic kidney diseaseDominant polycystic kidney diseaseGeneral risk factorsCystic kidney diseasePolycystic kidney diseaseAllograft nephropathyImmunosuppressive therapyRapamycin inhibitorsUltrasound evaluationDialysis treatmentRisk factorsCystic diseaseGeneral populationPatientsMalignancy susceptibilityCancer developmentMammalian targetCancerKidney